Therefore, we would suggest using 56.1% (N=83/148) as an estimate of the probability of responding to fluoxetine mono-therapy in phase I. According to Table 1 (CONSORT diagram), the number of patients who relapsed in phase II was nine with fluoxetine, 15 with lithium, and 14 with placebo. Therefore, the proportion of patients who had not relapsed at the end of phase II was 67.9% (N=19/28) for fluoxetine, 42.3% (N=11/26) for lithium, and 48.1% (N=13/27) for placebo. We note, however, that there were also patients who were lost to follow-up evaluation during phase II. If we conservatively assume that all patients who were lost to follow-up evaluation relapsed, then the percentage of patients who remained well would be computed as the percentage of patients who completed therapy, or 39.3% (N=11/28) for fluoxetine, 19.2% (N=5/26) for lithium, and 25.9% (N=7/27) for placebo.